MGMT and glioblastoma: In a phase III study of MGMT methylated glioblastoma (CENTRIC EORTC 26,071–22,072 study), the short half-life of cilengitide was considered to be one of the reasons for failure, suggesting that it may have had an insufficient inhibitory effect on angiogenesis (Stupp et al. 2014a, 2014b; Chinot 2014; Tucci et al. 2014).